LSV Asset Management grew its position in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 22.5% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 25,000 shares of the life sciences company’s stock after buying an additional 4,600 shares during the quarter. LSV Asset Management’s holdings in Illumina were worth $3,279,000 at the end of the most recent reporting period.
Several other large investors have also recently added to or reduced their stakes in the company. Evoke Wealth LLC grew its stake in Illumina by 9.2% during the fourth quarter. Evoke Wealth LLC now owns 4,265 shares of the life sciences company’s stock worth $559,000 after buying an additional 360 shares during the last quarter. Axxcess Wealth Management LLC bought a new stake in Illumina during the fourth quarter worth about $215,000. Midwest Financial Partners Investments Inc. bought a new stake in Illumina during the fourth quarter worth about $480,000. Nano Cap New Millennium Growth Fund L P bought a new stake in Illumina during the fourth quarter worth about $33,000. Finally, Global Retirement Partners LLC grew its stake in Illumina by 67.4% during the fourth quarter. Global Retirement Partners LLC now owns 1,229 shares of the life sciences company’s stock worth $161,000 after buying an additional 495 shares during the last quarter. 89.42% of the stock is owned by institutional investors.
Insider Activity at Illumina
In related news, Director Keith A. Meister sold 225,067 shares of the stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $145.55, for a total value of $32,758,501.85. Following the transaction, the director directly owned 3,604,441 shares in the company, valued at $524,626,387.55. This represents a 5.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Christensen Jakob Wedel sold 700 shares of the stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total transaction of $97,328.00. Following the completion of the transaction, the senior vice president owned 15,056 shares in the company, valued at $2,093,386.24. This represents a 4.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 330,160 shares of company stock valued at $48,028,308 in the last 90 days. 2.90% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
Get Our Latest Stock Report on Illumina
Illumina Stock Performance
ILMN stock opened at $145.23 on Wednesday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The company has a 50 day moving average price of $131.55 and a 200 day moving average price of $131.34. Illumina, Inc. has a fifty-two week low of $78.79 and a fifty-two week high of $155.53. The stock has a market capitalization of $21.97 billion, a PE ratio of 26.41, a price-to-earnings-growth ratio of 2.39 and a beta of 1.42.
Illumina (NASDAQ:ILMN – Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the previous year, the company posted $0.97 EPS. Illumina’s revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Analysts forecast that Illumina, Inc. will post 5.2 EPS for the current year.
About Illumina
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
Featured Articles
- Five stocks we like better than Illumina
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
